Evidence map›Paper›PMID 35373440›Full record

ArticleBJU international2022

Development and validation of a life expectancy calculator for US patients with prostate cancer.

Elizabeth C Chase, Alex K Bryant, Yilun Sun, William C Jackson, Daniel E Spratt, Robert T Dess, Matthew J Schipper

Abstract read
In one paragraph

Article in BJU international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Elizabeth C ChaseDepartment of Biostatistics, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-0452-2976
Alex K BryantDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-0194-8381
Yilun SunDepartment of Radiation Oncology, University Hospitals/Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0002-1341-382X
William C JacksonDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-8709-5978
Daniel E SprattDepartment of Radiation Oncology, University Hospitals/Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0002-5973-4741
Robert T DessDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-2331-3758
Matthew J SchipperDepartment of Biostatistics, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-6728-4720

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
NCI NIH HHS P30 CA046592
6 · The paper itself

Abstract

objectiveTo develop and validate an accurate, usable prediction model for other-cause mortality (OCM) in patients with prostate cancer diagnosed in the United States. MATERIALS AND

methodsModel training was performed using the National Health and Nutrition Examination Survey 1999-2010 including men aged >40 years with follow-up to the year 2014. The model was validated in the Prostate, Lung, Colon, and Ovarian Cancer Screening Trial prostate cancer cohort, which enrolled patients between 1993 and 2001 with follow-up to the year 2015. Time-dependent area under the curve (AUC) and calibration were assessed in the validation cohort. Analyses were performed to assess algorithmic bias.

resultsThe 2420 patient training cohort had 459 deaths over a median follow-up of 8.8 years among survivors. The final model included eight predictors: age; education; marital status; diabetes; hypertension; stroke; body mass index; and smoking. It had an AUC of 0.75 at 10 years for predicting OCM in the validation cohort of 8220 patients. The final model significantly outperformed the Social Security Administration life tables and showed adequate predictive performance across race, educational attainment, and marital status subgroups. There is evidence of major variability in life expectancy that is not captured by age, with life expectancy predictions differing by 10 or more years among patients of the same age.

conclusionUsing two national cohorts, we have developed and validated a simple and useful prediction model for OCM for patients with prostate cancer treated in the United States, which will allow for more personalized treatment in accordance with guidelines.

Indexed as

Prostatic NeoplasmsChildHumansLife ExpectancyMaleNutrition SurveysProstateProstate-Specific AntigenUnited StatesProstate-Specific Antigencalculatorcomorbiditieslife expectancyother-cause mortality#PCSM#prostate cancerprostate cancer#uroonc

Identifiers

PMID35373440
PMCPMC9474626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.